Assessing utility of single photon emission computed tomography (SPECT) scan in Alzheimer disease: correlation with cognitive severity.

Department of Neurology, Lexington VA Medical Center, KY 40536.
Alzheimer Disease and Associated Disorders (Impact Factor: 2.69). 02/1990; 4(1):14-23. DOI: 10.1097/00002093-199040100-00002
Source: PubMed

ABSTRACT Diagnosis of probable Alzheimer disease (AD) is made by a combination of characteristic clinical findings, when normal laboratory studies reveal no structural or metabolic cause of the dementia. Definite diagnosis of AD, however, can only be made with brain tissue examination. PET scanning reveals parietotemporal decreases in cerebral blood flow (CBF) and glucose metabolism that differentiate AD from normal elderly and from multi-infarct dementia. Preliminary studies suggest that similar defects in CBF are detectable in single photon emission computed tomography (SPECT) in AD. Utilizing the iodinated ligand [123I] HIPDM ([123I] hydroxyiodobenzylpropanediamine), we studied 19 patients with probable AD of varying severity, with emphasis on mild cases, to assess the utility of SPECT as a diagnostic test in AD. Parietotemporal perfusion on SPECT was decreased unilaterally or bilaterally in 16 of 19 AD patients, similar to the defects reported with PET. The degree and extent of decreased CBF on SPECT correlated with AD severity. Strong correlations were obtained between decreases in computer-generated ratios of parietal to cerebellar activity and the level of cognitive function. SPECT was read as normal (on the radiographic film) by the nuclear medicine physician in all cases with Mini-Mental State (MMS) score greater than 24, and showed bilateral parietal perfusion deficits in only 1 of 4 patients with MMS between 22 and 24. Ten of 12 patients with MMS less than or equal to 21 had bilateral parietal abnormalities; the other 2 had unilateral perfusion defects. All patients with MMS less than 15 were bilaterally abnormal. SPECT is less expensive and more widely available than PET, and may have an adjunctive role in diagnosis of AD and other dementias if utilized under the proper circumstances.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective. —To report the distribution of Mini-Mental State Examination (MMSE) scores by age and educational level.Design. —National Institute of Mental Health Epidemiologic Catchment Area Program surveys conducted between 1980 and 1984.Setting. —Community populations in New Haven, Conn; Baltimore, Md; St Louis, Mo; Durham, NC; and Los Angeles, Calif.Participants. —A total of 18 056 adult participants selected by probability sampling within census tracts and households.Main Outcome Measures. —Summary scores for the MMSE are given in the form of mean, median, and percentile distributions specific for age and educational level.Results. —The MMSE scores were related to both age and educational level. There was an inverse relationship between MMSE scores and age, ranging from a median of 29 for those 18 to 24 years of age, to 25 for individuals 80 years of age and older. The median MMSE score was 29 for individuals with at least 9 years of schooling, 26 for those with 5 to 8 years of schooling, and 22 for those with 0 to 4 years of schooling.Conclusions. —Cognitive performance as measured by the MMSE varies within the population by age and education. The cause of this variation has yet to be determined. Mini-Mental State Examination scores should be used to identify current cognitive difficulties and not to make formal diagnoses. The results presented should prove to be useful to clinicians who wish to compare an individual patient's MMSE scores with a population reference group and to researchers making plans for new studies in which cognitive status is a variable of interest.(JAMA. 1993;269:2386-2391)
    JAMA The Journal of the American Medical Association 05/1993; 269(18):2386. DOI:10.1001/jama.1993.03500180078038 · 30.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: An accurate etiological diagnosis in patients presenting with symptoms of cognitive decline is becoming progressively more important as new approaches to treatment are developed. Neuroimaging technology may play an important role in assisting in the diagnosis of various dementing disorders. A variety of neuroimaging methods have demonstrated varying degrees of sensitivity and specificity to the anatomical or physiological brain changes that accompany various dementing disorders. In addition to the clinical application of these techniques for diagnostic purposes, they also offer the opportunity to examine structural, functional, and biochemical changes in the brain that will lead to new insights regarding the pathophysiology of various dementias and advance our understanding about brain-behavior relationships. This paper reviews neuroimaging studies relevant to several of the most common non-Alzheimer's disease dementias including dementia with Lewy bodies, vascular dementia, frontotemporal dementia, primary progressive aphasia and semantic dementia. The particular imaging techniques covered will include high resolution structural imaging with magnetic resonance imaging and functional neuroimaging techniques such as single photon emission computed tomography, and positron emission tomography.
    Clinical Neuroscience Research 05/2004; DOI:10.1016/S1566-2772(04)00006-4 · 0.80 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is increasing evidence that deficient clearance of β-amyloid (Aβ) contributes to its accumulation in late-onset Alzheimer disease (AD). Several Aβ-degrading enzymes, including neprilysin (NEP), endothelin-converting enzyme (ECE), and angiotensin-converting enzyme (ACE) reduce Aβ levels and protect against cognitive impairment in mouse models of AD. In post-mortem human brain tissue we have found that the activity of these Aβ-degrading enzymes rise with age and increases still further in AD, perhaps as a physiological response that helps to minimize the build-up of Aβ. ECE-1/-2 and ACE are also rate-limiting enzymes in the production of endothelin-1 (ET-1) and angiotensin II (Ang II), two potent vasoconstrictors, increases in the levels of which are likely to contribute to reduced blood flow in AD. This review considers the possible interdependence between Aβ-degrading enzymes, ischemia and Aβ in AD: ischemia has been shown to increase Aβ production both in vitro and in vivo, whereas increased Aβ probably enhances ischemia by vasoconstriction, mediated at least in part by increased ECE and ACE activity. In contrast, NEP activity may help to maintain cerebral perfusion, by reducing the accumulation of Aβ in cerebral blood vessels and lessening its toxicity to vascular smooth muscle cells. In assessing the role of Aβ-degrading proteases in the pathogenesis of AD and, particularly, their potential as therapeutic agents, it is important to bear in mind the multifunctional nature of these enzymes and to consider their effects on other substrates and pathways.
    Frontiers in Aging Neuroscience 09/2014; 6:238. DOI:10.3389/fnagi.2014.00238 · 2.84 Impact Factor